AO-128, alpha-glucosidase inhibitor: antiobesity and antidiabetic actions in genetically obese-diabetic rats, Wistar fatty.
Antiobesity and antidiabetic actions of the alpha-glucosidase inhibitor AO-128 were examined using genetically obese-diabetic rats, Wistar fatty. Ten-week-old, male fatty rats were kept on CE-2 diet containing 10 or 25 ppm of AO-128 for 4 weeks. The average drug intake was calculated to be 0.74 or 1.78 mg/kg/day from the average food intake, respectively. The intestinal maltase and sucrase activities were decreased by AO-128 in a dose-related fashion. Food intake of fatty rats treated with AO-128 was decreased throughout the experiment. This decrease in food intake could hardly be explained only by diarrhea which occurred for the first 5 days of the administration of AO-128. AO-128 normalized hyperglycemia and markedly reduced hypertriglyceridemia and hyperinsulinemia in fatty rats. In addition, AO-128 decreased body weight gain, food efficiency, epididymal adipose tissue weight, carcass weight, and body fat deposition. These findings indicate that AO-128 may be useful for treating human obesity and diabetes.
Ikeda
H
H
Pharmaceutical Research Laboratories II, Takeda Chemical Industries Ltd., Osaka, Japan.
Odaka
H
H
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D003511:Cyclohexanols / Q000627:therapeutic use*; D003920:Diabetes Mellitus / Q000188:drug therapy*; D004435:Eating / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D065089:Glycoside Hydrolase Inhibitors; D008297:Male; D009765:Obesity / Q000188:drug therapy*; D051381:Rats; D017208:Rats, Wistar
D003511:Cyclohexanols; D004791:Enzyme Inhibitors; D065089:Glycoside Hydrolase Inhibitors; C054577:AO 128